{"entity":{"id":"concur","kind":"trial","name":"CONCUR","aka":[],"tldr":"The Asian repeat of CORRECT found a larger benefit, partly because fewer patients had already had targeted drugs.","summary":"CONCUR randomised 204 patients in mainland China, Hong Kong, South Korea, Taiwan and Vietnam 2:1 to regorafenib or placebo. Median overall survival was 8.8 against 6.3 months (hazard ratio 0.55, 95% CI 0.40 to 0.77, one-sided p=0.00016). Drug-related adverse events occurred in 97 percent of regorafenib recipients, with grade 3 or higher hand-foot skin reaction in 16 percent and hypertension in 11 percent. Fewer patients had received prior targeted therapy than in CORRECT, which may explain the larger effect, and the trial is why regorafenib carries a strong recommendation in Asian guidelines.","status":"positive","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01584830","url":"https://clinicaltrials.gov/study/NCT01584830"},{"label":"CONCUR: regorafenib in Asian patients with previously treated metastatic colorectal cancer (Lancet Oncology 2015)","url":"https://doi.org/10.1016/S1470-2045(15)70156-7"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["kinase-inhibitors","antiangiogenic"],"targets":["vegf"],"drugs":["regorafenib"],"companies":["bayer"],"institutions":[],"pathways":[],"terms":[],"trials":["correct"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01584830","phase":"3","setting":"Asian patients with refractory metastatic colorectal cancer after at least two previous lines: regorafenib against placebo","sponsor":"Bayer","result":"Median overall survival 8.8 against 6.3 months (hazard ratio 0.55).","yearReported":2015,"enrolled":204,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Regorafenib","n":136,"value":8.8},{"name":"Placebo","n":68,"value":6.3}],"hr":0.55,"ci":[0.4,0.77],"p":"0.00016 one-sided","source":"https://doi.org/10.1016/S1470-2045(15)70156-7"}],"replication":"Confirms CORRECT in a different population."},"route":"/trials/concur/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"company":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/"}],"trial":[{"id":"correct","kind":"trial","name":"CORRECT","route":"/trials/correct/"},{"id":"fresco-2","kind":"trial","name":"FRESCO-2","route":"/trials/fresco-2/"}]}}